Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03468985
Title Nivolumab, Cabozantinib S-Malate, and Ipilimumab in Treating Patients With Recurrent Stage IV Non-small Cell Lung Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors National Cancer Institute (NCI)
Indications

lung non-small cell carcinoma

Therapies

Cabozantinib + Nivolumab

Cabozantinib + Ipilimumab + Nivolumab

Nivolumab

Age Groups: adult | senior
Covered Countries USA

Additional content available in CKB BOOST